Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.
Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.
复制标题
DOI：
10.1007/s12609-012-0082-8
复制
发表时间：
2012-09-01
影响因子：
0.9
通讯作者：
Crew, Katherine D
中科院分区：
文献类型：
--
作者：
Reimers, Laura;Crew, Katherine D
选择性雌激素受体调节剂(SERM)和芳香酶抑制剂(AIS)的临床试验数据表明，在预防环境中，高危女性的乳腺癌发病率降低。我们对乳腺癌化学预防的临床试验和最近发表的报告进行了广泛的回顾，为卫生保健专业人员提供信息，以改善关于化学预防的决策。尽管这些试验取得了积极的结果，但由于在识别高危妇女方面存在障碍、缺乏对风险和益处的了解以及对副作用的担忧，化学预防的接受率一直较低。旨在增加吸烟率的干预措施收效甚微。临床医生可以通过有效地传达乳腺癌风险和加强对化学预防的风险和益处的知识，支持妇女在关于SERM和AIS的知情决策中。促进接受和坚持化学预防有望减少这种疾病的公共卫生负担。
Clinical trial data on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have demonstrated reduced breast cancer incidence in the prevention setting among high-risk women. We conducted an extensive review of clinical trials and recent published reports of barriers to uptake of breast cancer chemoprevention, to provide health care professionals with information to improve decision-making regarding chemoprevention. Despite the positive results of these trials, uptake of chemoprevention has been low due to barriers in identifying high-risk women, lack of understanding of risks and benefits, as well as concerns about side effects. Interventions designed to increase uptake have met with limited success. Clinicians can support women in informed decision-making about SERMs and AIs by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of chemoprevention. Promoting uptake and adherence to chemoprevention holds promise for reducing the public health burden of this disease.